Dr. Sartor on Remaining Questions With Sipuleucel-T in mCRPC

Oliver Sartor, MD
Published: Friday, Jul 21, 2017



Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer (mCRPC).

Sartor says more cellular studies need to be done with sipleucel-T in order to better understand the immune response and changes in the cells of patients treated with this agent.

Additionally, Sartor says, the activity of immunotherapy in ethnic groups should be explored further.
 
SELECTED
LANGUAGE


Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer (mCRPC).

Sartor says more cellular studies need to be done with sipleucel-T in order to better understand the immune response and changes in the cells of patients treated with this agent.

Additionally, Sartor says, the activity of immunotherapy in ethnic groups should be explored further.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x